Braveheart Bio Inc., a clinical-stage biopharmaceutical company backed by a16z, is seeking to raise as much as $318.8 million in an initial public offering, adding to a growing pipeline of listings in the sector.
Science Bloomberg Jul 30, 2026
A16z-Backed Biotech Braveheart Seeks $318.8 Million in US IPO
Braveheart Bio Inc., a clinical-stage biopharmaceutical company backed by a16z, is seeking to raise as much as $318.8 million in an initial public offering, adding to a growing pipeline of listings in the sector.
